Even if you are a natural late riser, if you’re ever faced with cancer, it might be time to make an exception. A study of ...

Atezolizumab addition to chemotherapy post-surgery showed no significant improvement in invasive disease-free survival for high-risk TNBC patients. The study reported a higher incidence of severe ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical trial collaboration and supply ...

Atezolizumab monotherapy improved overall survival for patients with advanced or metastatic non–small cell lung cancer (NSCLC) compared with single-agent chemotherapy, supporting the immunotherapy's ...

Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung ...

VIENNA -- Longer follow-up in the so-called IMpower010 trial further cements atezolizumab's (Tecentriq) value in treating stage II-IIIa non-small cell lung cancer (NSCLC) in patients with tumor cells ...

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results. Different ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...

The initial results of the IMbrave050 trial raised hopes that an effective adjuvant regimen for hepatocellular carcinoma (HCC) might finally have arrived. Patients with HCC treated with a combination ...

Both immunotherapy drugs work by blocking cancer cells’ ability to evade detection by the immune system, according to ...